Ascendis Pharma A/s logo

Ascendis Pharma A/s(NASDAQ) ASND

Market Cap$15.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-7%
5 Year+35%
1 Year+9%
1 Month-16%
$228.41
+1.04%
+2.36Today
Ascendis Pharma A/s last closing stock price
MetricPriceDate
Last closeUSD 228.412026-10-07
Ascendis Pharma A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.25%USD 227.832026-09-30
1 month-15.58%USD 270.562026-09-04
3 month-17.07%USD 275.432026-07-09
Year to date+7.11%USD 213.242025-12-31
1 year+8.84%USD 209.862025-10-07
3 year+152.44%USD 90.482023-10-06
5 year+34.94%USD 169.272021-10-08
Since inception-6.92%USD 245.382026-04-20

Ascendis Pharma A/s Financials at a Glance

Market Cap

$15.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€1.05B

Net Income (TTM)

€755.85M

EPS (TTM)

$13.12

P/E Ratio

16.47

Dividend

$0.00

Beta (Volatility)

0.74 (Low)

Price

$228.41

Volume

80

Open

$224.36

Previous Close

$228.41

Daily Range

$223.05 - $229.00

52-Week Range

$186.05 - $282.15

Estimated Earnings Date

Nov 11, 2026

ASND News

SellAlert-Blue.png

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma

Jonathan PoncianoMay 14, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ascendis Pharma A/s

Ascendis Pharma A/S is a biopharmaceutical company focused on developing innovative therapeutic solutions for critical medical conditions. The company is known for its flagship product, SKYTROFA, which addresses growth hormone deficiency (GHD). With a strong pipeline of TransCon-branded candidates, Ascendis aims to transform treatment paradigms in various therapeutic areas.

Products and Services
  • SKYTROFA for growth hormone deficiency
  • TransCon Growth Hormone for pediatric and adult GHD
  • TransCon parathyroid hormone for hypoparathyroidism
Growth Outlook
  • Recent quarterly revenue increased to €344.9 million, reflecting strong market demand
  • Development of TransCon CNP for pediatric achondroplasia shows promising potential
  • Expansion into new markets, including Japan, enhances growth opportunities
Financial Highlights
  • Net income for Q2 2026 reached €210.4 million, showcasing robust profitability
  • TTM gross profit margin stands at 90.2%, indicating strong operational efficiency
  • Current ratio of 2.99 suggests solid liquidity position
Ascendis Pharma A/S is positioned to capitalize on its innovative product offerings and expanding market presence. The company's commitment to addressing unmet medical needs through its advanced pipeline is a key driver of its growth strategy. Recent financial performance highlights, including significant revenue growth and strong profitability, further underscore the company's potential in the biopharmaceutical sector. With a focus on both existing and new therapeutic areas, Ascendis Pharma is well-equipped to navigate the evolving healthcare landscape.
AI Generated • Sep 19, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Jan Møller Mikkelsen

Website

www.ascendispharma.com

Headquarters

Hellerup, CR 2900, DK

ASND Financials

Key Financial Metrics (TTM)

Gross Margin

90.19%

Operating Margin

10.38%

Net Income Margin

71.69%

Return on Equity

190.44%

Return on Capital

-18.47%

Return on Assets

33.08%

Earnings Yield

6.07%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$15.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

65.67M

Volume

80

Avg. Volume

660.09K

Financials (TTM)

Gross Profit

€950.90M

Operating Income

€109.45M

EBITDA

€78.13M

Operating Cash Flow

€351.32M

Capital Expenditure

-€14.43M

Free Cash Flow

€336.90M

Cash & ST Invst.

€811.92M

Total Debt

€449.89M

Ascendis Pharma A/s Performance Analysis

Ascendis Pharma A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 53,782,560485.0%
20232023-12-31EUR 288,352,991436.1%
20242024-12-31EUR 393,347,10836.4%
20252025-12-31EUR 812,725,097106.6%
Ascendis Pharma A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3035.2%
Q42025-12-3114.8%
Q12026-03-312.2%
Q22026-06-3037.6%
Ascendis Pharma A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -10.9332.1%
20232023-12-31EUR -9.25-15.4%
20242024-12-31EUR -7.06-23.6%
20252025-12-31EUR -4.25-39.9%
Ascendis Pharma A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-22.0%
Q42025-12-3146.0%
Q12026-03-311935.2%
Q22026-06-30-68.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€344.90M

+118.2%

Gross Profit

€312.61M

+146.9%

Gross Margin

90.64%

N/A

Market Cap

$15.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$12.62M

N/A

Employees

1,189

N/A

Net Income

€210.40M

+641.5%

EBITDA

€68.08M

+2835.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€811.92M

+64.3%

Total Debt

€449.89M

-43.2%

Accounts Receivable

€224.01M

+102.8%

Inventory

€310.45M

+2.3%

Long Term Debt

€384.48M

+16.4%

Short Term Debt

€65.40M

-85.9%

Return on Assets

33.08%

N/A

Return on Invested Capital

6.01%

N/A

Free Cash Flow

€283.11M

+2524.1%

Operating Cash Flow

€286.35M

+4000.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NBIXNeurocrine Biosciences, Inc.
$143.47-1.40%
CORTCorcept Therapeutics Incorporated
$119.60+0.03%
BMRNBioMarin Pharmaceutical Inc.
$55.20-1.81%
INSMInsmed Incorporated
$101.74-3.32%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$30.65+3.44%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$158.91-3.26%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$32.07+0.75%
IBITiShares Bitcoin Trust
$47.21-2.64%

Questions About ASND

What is the current price of Ascendis Pharma A/s?

Ascendis Pharma A/s is trading at $228.41 per share.

What is the 52-week range for Ascendis Pharma A/s?

Over the past 52 weeks, Ascendis Pharma A/s has traded between $186.05 and $282.15.

How much debt does Ascendis Pharma A/s have?

As of the most recent reporting period, Ascendis Pharma A/s reported total debt of €514.57M.

How much cash does Ascendis Pharma A/s have on hand?

Ascendis Pharma A/s reported €928.66M in cash and cash equivalents in its most recent financial results.

What is Ascendis Pharma A/s’s dividend yield?

Ascendis Pharma A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services